# Clenbuterol to Target DUX4 in FSHD

> **NCT06721299** · PHASE1 · RECRUITING · sponsor: **Jeffrey Statland** · enrollment: 30 (estimated)

## Conditions studied

- Muscular Dystrophy, Facioscapulohumeral

## Interventions

- **DRUG:** Clenbuterol

## Key facts

- **NCT ID:** NCT06721299
- **Lead sponsor:** Jeffrey Statland
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-25
- **Primary completion:** 2028-02
- **Final completion:** 2028-07
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-02-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06721299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06721299, "Clenbuterol to Target DUX4 in FSHD". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT06721299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*